

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

BOSTON SCIENTIFIC CORP  
Form 8-K  
December 20, 2004

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

\_\_\_\_\_  
FORM 8-K  
\_\_\_\_\_

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 14, 2004

BOSTON SCIENTIFIC CORPORATION

-----  
(Exact name of registrant as specified in charter)

DELAWARE	1-11083	04-2695240
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission file number)	(IRS employer identification no.)

One Boston Scientific Place, Natick, Massachusetts 01760-1537

-----  
(Address of principal executive offices) (Zip code)

Registrant's telephone number, including area code: (508) 650-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

=====

ITEM 5.02. DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;  
APPOINTMENT OF PRINCIPAL OFFICERS.

On December 14, 2004, the Board of Directors of Boston Scientific Corporation (the "Company") appointed Paul A. LaViolette to the position of Chief Operating Officer of the Company. Prior to this appointment, Mr. LaViolette, 47, served as Senior Vice President and Group President for the Company's Cardiovascular businesses. Mr. LaViolette joined the Company in January 1994 as President of Boston Scientific International. In February 1995, he became Group President for the Company's Endoscopy and Urology businesses. In 1998, he again joined Boston Scientific International as its President to help strengthen and stabilize the organization. In 2000, Mr. LaViolette added Group President responsibilities for the Scimed, EP Technologies and Target divisions, and in 2001 also took on the role of President of Scimed.

During 2000, the Company provided a home improvement loan in the amount of \$400,000 to Mr. LaViolette. The principal balance on the loan bears interest at the then-current applicable federal rate for medium term notes (approximately 6%) until the principal balance is paid in full. Principal, together with interest compounded quarterly, is due and payable in October 2005.

The Company announced additional management promotions. A copy of the press release is attached hereto as Exhibit 99.1. The Company also provides retention and indemnification agreements to its executive officers. Forms of these agreements have been previously filed by the Company with the Securities and Exchange Commission.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

99.1 Press Release dated December 20, 2004

SIGNATURE

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BOSTON SCIENTIFIC CORPORATION

Date: December 20, 2004

By: /s/ Lawrence J. Knopf

-----  
Lawrence J. Knopf  
Vice President and  
Assistant General Counsel

INDEX TO EXHIBITS

Edgar Filing: BOSTON SCIENTIFIC CORP - Form 8-K

EXHIBIT  
NUMBER  
-----

DESCRIPTION  
-----

99.1

Press Release dated December 20, 2004